VS
Compare Harvest Healthcare Leaders Income ETF (HHL) vs Harvest Healthcare Leaders Income ETF (HHL.U) to find the best fit for your portfolio. HHL and HHL.U provide the same top sector exposures: Healthcare and Sovereign. When evaluating costs, HHL features a management fee (MER) of 0.85%, compared to 0.85% for HHL.U. Performance-wise, HHL has returned 0.32% year-to-date with +$354 M in net flows, whereas HHL.U is at 0.9% with +$4 M. Use the comparison tool below to benchmark these funds across top 10 holdings, yield, sector weights and historical returns.
NAV Performance and Flows
Key Data
Compare
HHL
HHL.U
| AuM | $1,833.20 M | $110.92 M |
| Management Fees | 0.85% | 0.85% |
| Exp. ratio | 0.98% | 0.98% |
| Tracking Difference | - | - |
Historical performance and flows
As of September 9, 2026
| 1M | 3M | YTD | 1Y | 3Y | ||
|---|---|---|---|---|---|---|
| Perf. | HHL | -3.52% | +4.74% | -0.32% | +8.86% | +18.71% |
HHL.U | -3.37% | +5.26% | +0.90% | +10.86% | +23.94% | |
| Flows | HHL | -$1 M | +$41 M | +$354 M | +$356 M | +$688 M |
HHL.U | +$1 M | +$2 M | +$4 M | +$5 M | +$41 M |
HHL vs HHL.U exposure
Countries
HHL
USA
84.21%
Other
15.79%
HHL.U
USA
84.21%
Other
15.79%
Sectors
HHL
Healthcare
98.89%
HHL.U
Healthcare
98.89%
As of September 9, 2026
Top 10 Holdings
HHL
Regeneron Pharmaceuticals, Inc.
5.34%
Boston Scientific Corp.
5.14%
Bristol Myers Squibb Co.
5.10%
Thermo Fisher Scientific, Inc.
5.00%
Merck & Co., Inc.
4.99%
Elevance Health, Inc.
4.99%
Amgen, Inc.
4.95%
Agilent Technologies, Inc.
4.95%
Intuitive Surgical, Inc.
4.94%
UnitedHealth Group, Inc.
4.94%
HHL.U
Regeneron Pharmaceuticals, Inc.
5.34%
Boston Scientific Corp.
5.14%
Bristol Myers Squibb Co.
5.10%
Thermo Fisher Scientific, Inc.
5.00%
Merck & Co., Inc.
4.99%
Elevance Health, Inc.
4.99%
Amgen, Inc.
4.95%
Agilent Technologies, Inc.
4.95%
Intuitive Surgical, Inc.
4.94%
UnitedHealth Group, Inc.
4.94%
Diversification
HHL
Total weight of top 10 holdings out of 25 total
50.34%
HHL.U
Total weight of top 10 holdings out of 25 total
50.34%
Characteristics
Compare
HHL
HHL.U
| Provider | Harvest Portfolios Group | Harvest Portfolios Group |
| Management | Actively managed | Actively managed |
| Benchmark | - | - |
| Replication Method | ||
| Asset Class | Equity | Equity |
| Dividend Policy | Distributing | Distributing |
| Trailing 12m distribution yield | 10.03% | 8.96% |
| Meets ESG criteria | No | No |
| Inception Date | December 18, 2014 | January 17, 2017 |
Frequently asked questions about HHL and HHL.U
Which ETF has performed better year to date: HHL or HHL.U?
As of September 9, 2026, HHL has returned -0.32% year to date, while HHL.U has returned 0.90%. HHL.U is ahead on YTD performance.
Which ETF is larger by assets under management: HHL or HHL.U?
As of September 9, 2026, HHL manages $1.83 B in assets, while HHL.U manages $110.92 M. HHL is the larger fund by AUM.
How are HHL and HHL.U managed?
HHL is actively managed by Harvest Portfolios Group. It does not track an index. HHL.U is actively managed by Harvest Portfolios Group. It does not track an index.
What sectors do HHL and HHL.U emphasize?
HHL is most exposed to Healthcare and Sovereign. HHL.U is most exposed to Healthcare and Sovereign.
Which ETF is attracting more investor flows: HHL or HHL.U?
Year to date, HHL has seen +$354.17 M in net flows, compared with +$4.36 M for HHL.U. HHL has attracted more net investor money so far.
How do the fees of HHL and HHL.U compare?
HHL has an expense ratio of 0.98%, while HHL.U has an expense ratio of 0.98%.
What are the top holdings of HHL and HHL.U?
HHL's largest holdings include Regeneron Pharmaceuticals, Inc., Boston Scientific Corp., and Bristol Myers Squibb Co.. HHL.U's top holdings include Regeneron Pharmaceuticals, Inc., Boston Scientific Corp., and Bristol Myers Squibb Co..
Which ETF is more diversified: HHL or HHL.U?
HHL holds 25 securities, while HHL.U holds 25. On holdings count, HHL is the more diversified portfolio.
Recent articles about HHL and HHL.U
The ETF Market Canada is brought to you by Cboe in partnership with Trackinsight SA who is providing all the data, analysis and editorial content on this site. Unless explicitly stated as such, any information that you receive is not real-time.
All content on the ETF Market Canada is for your general information use only, Cboe is not responsible for any use of content by you outside this scope. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by Cboe and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All content on the ETF Market Canada is for your general information use only, Cboe is not responsible for any use of content by you outside this scope. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by Cboe and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.